ProCE Banner Activity

FAQs: Optimizing the Care of Patients With Relapsed/Refractory MCL

Clinical Thought

In this commentary, international expert faculty address frequently asked questions about the selection and sequencing of BTK inhibitors for patients with relapsed/refractory mantle cell lymphoma.

Released: April 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Caribou, Daiichi Sankyo, Genentech, Kite, Lilly, MEI Pharma, MorphoSys, Pharmacyclics, Seattle Genetics.

Marco Ladetto, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, Amgen, AstraZeneca, EUSA Pharma, Gentili, Gilead/Kite, Incyte, Johnson & Johnson, Jazz, Lilly, Regeneron, Roche.

Max Topp, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Janssen, Kite, Roche.